Plato Investment Management Ltd Boosts Stake in Merck & Co., Inc. $MRK

Posted by Stanley Muller on Aug 26th, 2026

Plato Investment Management Ltd grew its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 15.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 74,299 shares of the company’s stock after buying an additional 9,877 shares during the quarter. Plato Investment Management Ltd’s holdings in Merck & Co., Inc. were worth $9,492,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Bell Investment Advisors Inc increased its position in shares of Merck & Co., Inc. by 23.0% during the second quarter. Bell Investment Advisors Inc now owns 4,499 shares of the company’s stock valued at $578,000 after acquiring an additional 842 shares during the last quarter. Hexagon Capital Partners LLC grew its stake in Merck & Co., Inc. by 2.5% in the 2nd quarter. Hexagon Capital Partners LLC now owns 13,420 shares of the company’s stock valued at $1,724,000 after purchasing an additional 322 shares during the period. Roman Butler Fullerton & Co. increased its position in shares of Merck & Co., Inc. by 2.9% during the 2nd quarter. Roman Butler Fullerton & Co. now owns 8,695 shares of the company’s stock valued at $1,078,000 after purchasing an additional 244 shares during the last quarter. Simplicity Wealth LLC increased its position in shares of Merck & Co., Inc. by 20.4% during the 2nd quarter. Simplicity Wealth LLC now owns 53,267 shares of the company’s stock valued at $6,845,000 after purchasing an additional 9,009 shares during the last quarter. Finally, Baxter Bros Inc. raised its stake in shares of Merck & Co., Inc. by 8.6% during the 2nd quarter. Baxter Bros Inc. now owns 10,391 shares of the company’s stock worth $1,335,000 after purchasing an additional 824 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MRK. Royal Bank Of Canada lowered shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and increased their price target for the company from $142.00 to $150.00 in a research report on Thursday, August 20th. Jefferies Financial Group downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. The Goldman Sachs Group increased their price objective on Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a report on Friday, August 21st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $147.60.

Get Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Up 3.9%

Shares of NYSE MRK opened at $156.54 on Wednesday. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The business has a 50-day simple moving average of $129.64 and a two-hundred day simple moving average of $121.80. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market cap of $386.22 billion, a P/E ratio of 125.23, a P/E/G ratio of 6.32 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the prior year, the business posted $2.13 earnings per share. The company’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Positive topline INTerpath-001 results strengthened expectations that the vaccine could extend KEYTRUDA’s growth runway and create a potentially important new oncology franchise. Merck Surges on a Melanoma Win
Positive Sentiment: Analysts raised their valuation expectations: Wolfe Research increased its price target to $180 and assigned an “outperform” rating, while Argus raised its target to $170 and reiterated a “buy” rating. Wolfe Research Price Target
Positive Sentiment: Investors are also anticipating a concentrated series of regulatory decisions and clinical readouts this fall, which could produce additional upside if Merck’s pipeline delivers. What Would It Take to Get MRK Stock to $200?
Neutral Sentiment: The cancer-vaccine opportunity remains early. The available evidence is limited, and potential barriers include manufacturing complexity, cost, patient selection, and the need for regulatory review and broader clinical validation. How the Merck/Moderna Cancer Vaccine Works
Negative Sentiment: After the recent rally, MRK is trading near or above several analysts’ prior targets, leaving less room for disappointment and making future gains increasingly dependent on successful trial results, FDA decisions, and evidence that the post-KEYTRUDA growth strategy can scale.

Insiders Place Their Bets

In other news, EVP David Michael Williams sold 52,847 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. This trade represents a 21.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.